Skip to content
ETopical – Lifestyle
Home
Sample Page
Author:
NurExone Biologic Inc
NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
August 28, 2026
NurExone Announces Annual General and Special Meeting to Consider Share Consolidation in Support of U.S. Capital Markets Strategy
August 21, 2026
NurExone Announces Closing of C$1,066,078 Private Placement
August 20, 2026
NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model
August 14, 2026
NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership
August 12, 2026
NurExone Launches Bioprocess Optimization Initiative to Support Commercial and Clinical Readiness
July 30, 2026
Corporate Updates – NurExone appoints Mr. David Stolick to the Board of Directors
July 28, 2026
NurExone Announces Closing of Non-Brokered Private Placement
June 30, 2026
Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico
June 24, 2026
NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
June 1, 2026
1
2
Next Page
→